DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR LYNPARZA
Clinical Trials for LYNPARZA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | Active, not recruiting | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2010-03-01 | This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well cediranib maleate and olaparib work compared to olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or triple-negative breast cancer that has returned after a period of improvement. Cediranib maleate may help keep cancer cells from growing by affecting their blood supply. Olaparib may stop cancer cells from growing abnormally. The combination of cediranib maleate and olaparib may help to keep cancer from growing. |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | Recruiting | Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet | Phase 3 | 2014-04-01 | Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | Recruiting | Breast International Group | Phase 3 | 2014-04-01 | Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | Recruiting | Frontier Science & Technology Research Foundation, Inc. | Phase 3 | 2014-04-01 | Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | Recruiting | Myriad Genetic Laboratories, Inc. | Phase 3 | 2014-04-01 | Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LYNPARZA
Condition Name
Clinical Trial Locations for LYNPARZA
Trials by Country
Clinical Trial Progress for LYNPARZA
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for LYNPARZA
Sponsor Name
